JP2021517128A - レボドパ分割用量組成物および使用 - Google Patents

レボドパ分割用量組成物および使用 Download PDF

Info

Publication number
JP2021517128A
JP2021517128A JP2020546876A JP2020546876A JP2021517128A JP 2021517128 A JP2021517128 A JP 2021517128A JP 2020546876 A JP2020546876 A JP 2020546876A JP 2020546876 A JP2020546876 A JP 2020546876A JP 2021517128 A JP2021517128 A JP 2021517128A
Authority
JP
Japan
Prior art keywords
levodopa
carbidopa
tablet
patient
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517128A5 (enExample
Inventor
エヌ． チェイス、トーマス
エヌ． チェイス、トーマス
イー． クラレンス−スミス、キャスリーン
イー． クラレンス−スミス、キャスリーン
Original Assignee
アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー
アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー, アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー filed Critical アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー
Publication of JP2021517128A publication Critical patent/JP2021517128A/ja
Publication of JP2021517128A5 publication Critical patent/JP2021517128A5/ja
Priority to JP2022110134A priority Critical patent/JP2022133449A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2020546876A 2018-03-29 2019-03-28 レボドパ分割用量組成物および使用 Pending JP2021517128A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022110134A JP2022133449A (ja) 2018-03-29 2022-07-08 レボドパ分割用量組成物および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650012P 2018-03-29 2018-03-29
US62/650,012 2018-03-29
PCT/US2019/024464 WO2019191353A1 (en) 2018-03-29 2019-03-28 Levodopa fractionated dose composition and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022110134A Division JP2022133449A (ja) 2018-03-29 2022-07-08 レボドパ分割用量組成物および使用

Publications (2)

Publication Number Publication Date
JP2021517128A true JP2021517128A (ja) 2021-07-15
JP2021517128A5 JP2021517128A5 (enExample) 2021-08-26

Family

ID=68060752

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546876A Pending JP2021517128A (ja) 2018-03-29 2019-03-28 レボドパ分割用量組成物および使用
JP2022110134A Pending JP2022133449A (ja) 2018-03-29 2022-07-08 レボドパ分割用量組成物および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022110134A Pending JP2022133449A (ja) 2018-03-29 2022-07-08 レボドパ分割用量組成物および使用

Country Status (7)

Country Link
US (3) US11033521B2 (enExample)
EP (1) EP3773532A4 (enExample)
JP (2) JP2021517128A (enExample)
CN (1) CN111954523A (enExample)
BR (1) BR112020017422A2 (enExample)
CA (1) CA3095341A1 (enExample)
WO (1) WO2019191353A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022133449A (ja) * 2018-03-29 2022-09-13 アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー レボドパ分割用量組成物および使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022044045A1 (en) * 2020-08-26 2022-03-03 Rubicon Research Private Limited Modified release formulations of levodopa

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502987A (ja) * 2005-08-05 2009-01-29 オスモティカ・コーポレイション カルビドパとレボドパを含有する延長放出型固形医薬組成物
JP2009543761A (ja) * 2006-05-31 2009-12-10 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング レボドパ／カルビドパの長期間２４時間腸内投与
JP2012527447A (ja) * 2009-05-19 2012-11-08 ニューロデルム リミテッド ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
WO2014141261A1 (en) * 2013-03-13 2014-09-18 Neuroderm Ltd Method for treatment of parkinson's disease
WO2016083863A1 (en) * 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061494A (en) * 1990-06-14 1991-10-29 The Upjohn Comany Tri-scored drug tablet
CN1960712B (zh) * 2004-05-21 2011-04-20 阿库-伯雷克技术公司 包含多个片段的刻痕药片
US7838031B2 (en) 2004-05-21 2010-11-23 Lawrence Solomon Method of administering a partial dose using a segmented pharmaceutical tablet
JP5395355B2 (ja) * 2004-05-21 2014-01-22 アキュ−ブレイク テクノロジーズ インコーポレーテッド ２個またはそれ以上の単位セグメントを含む医薬錠剤
US8506999B2 (en) 2005-05-23 2013-08-13 Accu-Break Technologies, Inc. Pharmaceutical tablets comprising a plurality of segments
AU2005338350A1 (en) 2005-11-18 2007-05-24 Solapharm, Inc. Segmented pharmaceutical dosage forms
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
UA106877C2 (uk) * 2008-08-22 2014-10-27 Вокхардт Рісерч Сентер Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення
HK1211836A1 (en) * 2013-03-28 2016-06-03 Omniactive Health Technologies Limited Neuroprotective effect of carotenoids in brain
WO2018034626A1 (en) * 2016-08-18 2018-02-22 İlko İlaç Sanayi Ve Ticaret Anonim Şirketi Antiparkinson tablet formulation with improved dissolution profile
CN111954523A (zh) * 2018-03-29 2020-11-17 艾维制药有限责任公司 左旋多巴分次剂量组合物及用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502987A (ja) * 2005-08-05 2009-01-29 オスモティカ・コーポレイション カルビドパとレボドパを含有する延長放出型固形医薬組成物
JP2009543761A (ja) * 2006-05-31 2009-12-10 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング レボドパ／カルビドパの長期間２４時間腸内投与
JP2012527447A (ja) * 2009-05-19 2012-11-08 ニューロデルム リミテッド ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物
WO2014141261A1 (en) * 2013-03-13 2014-09-18 Neuroderm Ltd Method for treatment of parkinson's disease
WO2016083863A1 (en) * 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022133449A (ja) * 2018-03-29 2022-09-13 アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー レボドパ分割用量組成物および使用

Also Published As

Publication number Publication date
US20210220308A1 (en) 2021-07-22
US20200121626A1 (en) 2020-04-23
EP3773532A1 (en) 2021-02-17
US20230233496A1 (en) 2023-07-27
US11439613B2 (en) 2022-09-13
CA3095341A1 (en) 2019-10-03
US11819485B2 (en) 2023-11-21
JP2022133449A (ja) 2022-09-13
EP3773532A4 (en) 2022-11-02
CN111954523A (zh) 2020-11-17
BR112020017422A2 (pt) 2020-12-22
US11033521B2 (en) 2021-06-15
WO2019191353A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
US11318144B2 (en) Compositions and methods for treating Alzheimer's disease and Parkinson's disease
EP2900230B1 (en) Compounds for the treatment of obesity and methods of use thereof
CN110996987A (zh) 用于调控应激障碍中激素级联的组合物和方法
EP4171539A1 (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
US11819485B2 (en) Levodopa fractionated dose composition and use
AU2023202003A1 (en) Melatonin mini-tablets and method of manufacturing the same
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
WO2020019938A1 (zh) 一种用于治疗肌萎缩性脊髓侧索硬化症的联合用药组合物及其制备方法和用途
HK40037691A (en) Levodopa fractionated dose composition and use
KR100816140B1 (ko) 일차성 두통의 치료에서 비타민 혼합물의 용도
EP4480474A1 (en) Pharmaceutical composition for treatment of parkinson's disease
GB2321190A (en) Medicament pack for treating Parkinson's Disease
HK40120004A (en) Melatonin mini-tablets and method of manufacturing the same
US20160220561A1 (en) Pharmaceutical composition of bupropion and naltrexone
US20160220562A1 (en) Pharmaceutical composition of bupropion and naltrexone
JPH10279497A (ja) β−アミノ酸吸収抑制剤
JPS59184124A (ja) 腎不全、糖尿病及び糖尿病性腎症におけるエネルギー代謝改善剤
HK1213190B (en) Compounds for the treatment of obesity and methods of use thereof
JPH09136843A (ja) 血圧上昇薬
JPH06279282A (ja) 鎮痛製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201119

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210702

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308